Jasper Therapeutics Inc (JSPR NASDAQ) stock market data APIs
$5.4988
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
Jasper Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Prev. Close
5.4988
Open
5.4988
High
5.8532
Low
5.4934
52 wk Range
3.13-26.05
Market Cap
83 373 K
Shares Outstanding
15 022 K
EPS
-1.41
Beta
2.725
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Jasper Therapeutics Inc data using free add-ons & libraries
Get Jasper Therapeutics Inc Fundamental Data
Jasper Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -81 605 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -1.4765
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Jasper Therapeutics Inc News
New
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower li...
Jasper Therapeutics' SWOT analysis: briquilimab's potential in CSU stock scrutinized
Jasper Therapeutics (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic spontaneous urticaria (CSU) and other mast-cell mediated diseases, has been garnering attent...
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antib...
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Jasper Therapeutics, Inc. (JSPR) was one of the stocks that was covered in that article. Wall Street analysts belie...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
